AnaptysBio Sets Estimated IPO Pricing Range

San Diego-based AnaptysBio, which develops antibodies for treating inflammation, has set its estimated IPO pricing range, saying on Tuesday that it expects to price its IPO at between $14.00 and $16.00 per share. The company is selling 4,000,000 shares of its common stock on the NASDAQ Global Select Market as ANAB. AnaptysBio is backed by Frazier Healthcare, Novo A/S, Avalon Ventures, Alloy Ventures, Biotechnology Value Fund, HBM Healthcare Investments, and others. The IPO follows one of the most active IPO and mergers and acquisitions years for Southern California last year, in 2016, and comes ahead of an anticipated IPO announcement for Venice-based Snap, Inc. as early as Thursday.